These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 38520605)

  • 21. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
    Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
    Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
    Rolfo C; Caglevic C; Santarpia M; Araujo A; Giovannetti E; Gallardo CD; Pauwels P; Mahave M
    Adv Exp Med Biol; 2017; 995():97-125. PubMed ID: 28321814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon.
    Ahmed Y; Berenguer-Pina JJ; Mahgoub T
    Oncology; 2021; 99(10):673-680. PubMed ID: 34280931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody Drug Conjugates in Lung Cancer.
    Merle G; Friedlaender A; Desai A; Addeo A
    Cancer J; 2022 Nov-Dec 01; 28(6):429-435. PubMed ID: 36383905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.
    Wei Q; Li P; Yang T; Zhu J; Sun L; Zhang Z; Wang L; Tian X; Chen J; Hu C; Xue J; Ma L; Shimura T; Fang J; Ying J; Guo P; Cheng X
    J Hematol Oncol; 2024 Jan; 17(1):1. PubMed ID: 38178200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies.
    Kang X; Zhou L; Jian YM; Lan SA; Xu F
    Med Sci Monit; 2018 Mar; 24():1408-1416. PubMed ID: 29515096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC).
    Zhang J; Zhou ZZ; Chen K; Kim S; Cho IS; Varadkar T; Baker H; Cho JH; Zhou L; Liu XM
    Cells; 2023 Sep; 12(19):. PubMed ID: 37830607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-Drug Conjugates-A Tutorial Review.
    Baah S; Laws M; Rahman KM
    Molecules; 2021 May; 26(10):. PubMed ID: 34063364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Loganzo F; Sung M; Gerber HP
    Mol Cancer Ther; 2016 Dec; 15(12):2825-2834. PubMed ID: 27780876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.
    Ceci C; Lacal PM; Graziani G
    Pharmacol Ther; 2022 Aug; 236():108106. PubMed ID: 34990642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.
    Girard N
    Curr Treat Options Oncol; 2022 Nov; 23(11):1626-1644. PubMed ID: 36242712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
    Belluomini L; Avancini A; Sposito M; Milella M; Rossi A; Pilotto S
    Expert Opin Biol Ther; 2023; 23(11):1077-1087. PubMed ID: 36995069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
    Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
    J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The application of HER2-ADC in future: More than expression.
    Zhou J; He H; Wang S; Li N
    Med; 2024 Mar; 5(3):173-175. PubMed ID: 38460494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of resistance to chemotherapy in non-small cell lung cancer.
    Min HY; Lee HY
    Arch Pharm Res; 2021 Feb; 44(2):146-164. PubMed ID: 33608812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.
    Schwach J; Abdellatif M; Stengl A
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):240. PubMed ID: 36042167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.